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Abstract 
Background: Methotrexate alone or in combination with other agents is the standard treatment for 
moderate-to-severe rheumatoid arthritis.  As the biological agents are expensive, they are not usually 
used until methotrexate has failed to give a good response. Thus, there is scope for the development 
of cheaper drugs that can be used instead of methotrexate or in addition to methotrexate.  
Objectives/methods: Pamapimod is a p38α inhibitor being developed for use in the treatment of 
rheumatoid arthritis.  The objective was to evaluate the recent clinical trials of pamapimod in subjects 
with rheumatoid arthritis.  Results: There is no clear cut evidence that pamapimod alone or in the 
presence of methotrexate is efficacious in subjects with rheumatoid arthritis, but it does cause 
adverse effects. Conclusion: It is unlikely that pamapimod will be useful in the treatment of rheumatoid 
arthritis. 







Rheumatoid arthritis is a debilitating cell mediated disorder that affects around 1% of the global 
population. People of any age can be affected, but it is particularly common in the 40-70 year old age 
group, and 2-3 times more common in females than males.  The predominant effect of rheumatoid 
arthritis is to impair daily living activities, but it also reduces life expectancy by 5-10 years, and 
increases the risk of cardiovascular death [1]. 
The cause of rheumatoid arthritis is unknown, but it is associated with autoimmunity responses that 
may be primary or secondary events [1].  Rheumatoid arthritis progresses to uncontrolled 
inflammation and destruction of bone and cartilage [1].  The cells that have roles in the 
pathophysiology of rheumatoid arthritis are CD4 T cells, mononuclear phagocytes, fibroblasts, 
osteoclasts, and neutrophils, which produce numerous inflammatory mediators including tumour 
necrosis factor (TNF)-α and interleukins (IL) -1, -6, and -11 [1]. 
Analgesics are used to relieve the pain associated with rheumatoid arthritis, and disease-modifying 
antirheumatic drugs (DMARDs) are used to modify the course of the disease [1]. The DMARDs are 
xenobiotic (e.g. methotrexate, sulfasalazine, chloroquine/hydroxychloroquine) or biological agents 
(e.g. inhibitors of TNF; etanercept, infliximab, and adalimumab, or of the interleukin-1 receptor; 
anakinra) [1].  Of the xenobiotic agents, methotrexate and sulfasalazine are the ones that give the 
least time to onset of action and highest frequency of remissions [1].  Methotrexate alone or in 
combination with other agents is the standard treatment for moderate-to-severe rheumatoid arthritis, 
with an initial dose of 15 mg/week orally titrated up to a target dose of 25-30 mg/week or maximal 
tolerated dose [1].  As the biological agents are expensive, they are not usually used until 
methotrexate has failed to give a good response [1]. 
One of the mitogen-activated protein kinases (MAPKs), p38α, is a regulator of proinflammatory 
mediators TNFα, IL-1, IL-6 and IL-8 [2].  These cytokines, in turn, regulate COX-2/PG2 (involved in 
joint swelling and pain), receptor activation of NF-κB ligand (RANKL), integrins, and matrix 
metalloproteinases (MMPs), which are involved in bone and cartilage destruction, and leukotrienes, 
which are involved (with MMPs) in the reduced lung function observed in rheumatoid arthritis [2].  This 
suggested that p38α inhibitors would also be useful in the treatment of rheumatoid arthritis.  
Pamapimod is a selective p38α inhibitor, which is being developed for use in the treatment of 
rheumatoid arthritis, and this evaluation is of the recent clinical trials with pamapimod. 
2. The story so far 
2.1 Preclinical studies with pamapimod 
There are 4 isoforms of p38, with the α-isoform being the one most implicated in inflammation. 
Pamapimod has no effect on p38γ or p38δ, but inhibits p38α and p38β with IC50 (concentration that 
causes 50% inhibition) values of 14 and 480 nM, respectively [3]. In this concentration range, 
pamapimod also inhibited Jnk1, Jnk2, and Jnk3, but was much less effective at activating these 
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kinases in cellular preparations, whereas the inhibitory activity of p38α was retained in cellular 
preparations [3].  Pamapimod also inhibited the production of TNFα and IL-1β in human whole blood 
stimulated with lipopolysaccharide (LPS) [3].   
In vivo, pamapimod reduced pain in a rat model of acute inflammation/pain (Brewer’s yeast-induced 
paw hyperalgesia) when administered, at 10-100 mg, 2 hours after the Brewer’s yeast [3]. In this 
model, pamapimod decreased the LPS-induced increases in TNFα and IL-6 levels [3].  In a mouse 
chronic model of rheumatoid arthritis (collagen-induced), oral pamapimod, administered four weeks 
after the collagen, reduced bone damage [3].  In synovial explants from subjects with rheumatoid 
arthritis, pamapimod inhibited the spontaneous production of TNFα with an IC50 of 104 nM [3].  These 
very promising preclinical results with pamapimod led to clinical trials. 
2.2 Methotrexate 
Methotrexate is the standard treatment for moderate-to-severe rheumatoid arthritis.  The mechanism 
of action of methotrexate in rheumatoid arthritis is unknown [1.  However, it is known that 
methotrexate inhibits dihydrofolate reductase and causes extracellular release of adenosine, which 
inhibits immune and inflammatory processes [1].   
2.3 Comparison with methotrexate 
2.3.1 Methods and results 
The efficacy and safety of pamapimod, compared with methotrexate in subjects with active 
rheumatoid arthritis was first evaluated in a 12 week double-blind clinical trial [4], and is summarised 
in this section. The 204 subjects enrolled were from 61 international centres, and were not receiving 
methotrexate; but approximately 50% of the subjects were using corticosteroids at doses equal to ≤10 
mg prednisone once daily.  Subjects were then randomised to pamapimod at 50 mg, 150 mg or 300 
mg once daily, or to methotrexate 7.5 mg/week increasing to 20 mg/week for 12 weeks.  All subjects 
also received folic acid at 5 mg/week throughout the trial to reduce toxicity with methotrexate. 
Previous therapy for rheumatoid arthritis of methotrexate, or a mean of 2 disease-modifying 
antirheumatic drugs (DMARDs), or anti-TNF medication was reported by 37%, 56% and 2-8% of 
subjects, respectively.  
The primary efficacy end point was the proportion of subjects with a 20% improvement response 
(ACR20) in the American College of Rheumatology (ACR) criteria at 12 weeks. The ACR20 response 
was significantly lower in the pamapimod group (23%, 18% and 31% at 50 mg, 150 mg and 300 mg, 
respectively), than in the methotrexate group (45%).  
Secondary efficacy end points included the ACR50 and ACR70, which were again lower in the 
pamapimod group, compared to the methotrexate group.  Of the 8 ACR core component criteria, only 
subjects in the 300 mg pamapimod group showed improvement in joint scores comparable with 
methotrexate; but disease activity and pain assessment scores did not improve for those subjects. A 
decrease from baseline in the mean Disease Activity Score in 28 joints (DAS28) occurred in all 
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subjects, with the greatest improvements in the methotrexate group. A reduction in fatigue assessed 
by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores was reported in all 
treatment groups, as well as a decline in the duration of morning stiffness to ≤45 minutes.  
C-reactive protein (CRP) levels increased for all subjects in the 50 mg and 150 mg pamapimod 
groups.  In contrast, in the first 2 weeks for the 300 mg pamapimod group, there was an initial 
decrease in CRP levels, which was not maintained after that, with levels fluctuating around baseline 
until the end of the trial. 
Adverse events lead to the withdrawal from treatment from the pamapimod groups of 6%, 8% and 
21% at 50mg, 150 mg and 300 mg, respectively, compared to 8% of the methotrexate group. For the 
90% of subjects who completed the trial infections/infestations was the most frequently reported 
adverse event, occurring in 25% of subjects from the methotrexate group, with similar numbers for the 
50 mg and 150 mg pamapimod group (23% and 27%, respectively), but in a significantly higher 
numbers (35%) of subjects from the 300 mg pamapimod group. 
Subjects receiving the higher dose of pamapimod also reported an increase in skin, gastrointestinal 
and nervous system disorders (particularly dizziness), compared to the lower dose pamapimod and 
methotrexate groups. Significant increases (≥ 2 times, upper normal level) of the liver enzymes, 
alanine aminotransferase and aspartate aminotransferase, occurred in both methotrexate and 
pamapimod groups (11% and 8%, respectively), with the highest percentage (19%) reported in 
subjects from the 300 mg pamapimod group. Elevated levels of creatine phosphokinase was more 
common with methotrexate (6%), than with the higher dose, 150 mg and 300 mg pamapimod groups 
(3%), and lowest dose 50 mg (0%). 
2.3.2 Discussion 
This was the first large scale randomised trial that evaluated the safety and efficacy of pamapimod 
and compared it to escalating doses of methotrexate over a 12 week period, and showed it to be 
inferior [4]. Thus, subjects with active rheumatoid arthritis treated with monotherapy pamapimod had 
reduced rates of disease response, and increased rates of adverse events, when compared to 
methotrexate [4]. The adverse events and toxicities reported were also consistent with those seen in 
studies of other p38 MAP kinase inhibitors, and were most likely class related [5].   
As pamapimod is clearly not suitable for use as an alternative to methotrexate, it was then considered 
as a possible add-on to treatment with methotrexate.  Firstly, a study was undertaken to determine 
whether pamapimod interacted with methotrexate (next section) and then methotrexate and 
pamapimod were compared to methotrexate alone (Section 4). 
3. Does pamapimod interact with methotrexate? 
3.1 Methods and results 
The methods and results of the proof-of-concept and drug-drug interaction study, demonstrating that 
coadministration of pamapimod and methotrexate over 10 days for the treatment of rheumatoid 
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arthritis did not show any clinically significant interactions [5], are summarised in this section. This 
study enrolled subjects with rheumatoid arthritis who had been receiving methotrexate for ≥12 weeks 
and were on a stable dose (10-20 mg/week) for 4 weeks prior to commencement. The subjects also 
had a normal creatinine clearance of >50 mL/min. All subjects met the criteria for the diagnosis of 
rheumatoid arthritis as defined by the American Rheumatism Association (ARA), but active disease 
was not a requirement for inclusion. 
The 22 subjects enrolled into this 2 week study were recruited from 4 International centres, and the 
median methotrexate dose was 15 mg/week.  All subjects were also receiving folic acid (≥5 mg/week), 
and were on stable doses of corticosteroids (≤ 10 mg/dl), hydroxychloroquine, or nonsteroidal 
antiinflammatory drugs (NSAIDs) for ≥ 4 weeks prior to commencement. Subjects were randomised 
3:1 to receive 300 mg pamapimod once daily or to placebo from days 5 to 14, respectively; taken 
within 10 minutes of breakfast where approximately 30% of calories were obtained from fat.  All 
subjects received methotrexate on day 1 and 8. Two patients from the pamapimod group were 
withdrawn early due to breaches in methotrexate dosing. 
Disease status parameters including a tender joint count (TJC), swollen joint count (SJC), erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP) and a Patient’s Global Health Assessment were 
evaluated on days 5 and 14. All parameters except the CRP were then used to calculate a subject’s 
Disease Activity Scores (DAS28). Group means for all parameters decreased in the subjects 
receiving pamapimod and methotrexate; for subjects receiving placebo and methotrexate a decrease 
was only noted in the SJC.  
The area under the curve (AUC) values obtained examining the effect of methotrexate on the 
pharmacokinetics of pamapimod and its metabolites on days 7 and 8 with and without methotrexate 
were comparable; however the maximum plasma concentration (Cmax) of pamapimod and its 
metabolites was 19% lower when coadministered with methotrexate. The effect of pamapimod on the 
pharmacokinetics of methotrexate on day 8 was also minimal, with the data obtained AUC and Cmax 
being comparable to that with methotrexate alone on day 7. The AUC value and Cmax of the 
metabolite 7-hydroxy-methotrexate increased by 26% and 20%, respectively, but the renal clearance 
and the percentage of dose recovered was similar with or without coadministration of pamapimod. 
The activity of 7-hydroxy-methotrexate was noted as being ~10% of that of methotrexate. 
For the 91% of subjects who completed the study a total of 76 mostly mild adverse events (AE) were 
reported, and the event rate was comparable between both groups. After commencing pamapimod on 
day 5, approximately 90% (19 of 21 subjects) reported dizziness and/or headache, with 25% of the 
patients in the pamapimod group recording multiple episodes that accounted for 86% of the events 
reported. No infections developed in the placebo group; however 33% (5 of 15) of subjects in the 
pamapimod group reported mild infections including folliculitis (most common), nasopharyngitis and 
urinary tract infection. Aspartate aminotransferase levels were normal for all subjects throughout the 
study, but 4 subjects developed elevated alanine aminotransferase levels that peaked within 2 days of 
receiving methotrexate and pamapimod on day 10, and then declined to near or near normal levels 
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for all but one subject by day 21. Safety assessment using vital signs and 12-lead ECG revealed no 
clinically significant changes throughout the study. 
 3.2 Discussion 
This study showed that coadministration of pamapimod with no adjustment of methotrexate dose over 
10 days did not show any clinically significant drug-drug interactions [5]. The authors claim that 
pamapimod showed efficacy in rheumatoid arthritis [5], and this is discussed in Expert Opinion 
Section (Section 5). 
4. In subjects receiving stable methotrexate 
4.1 Methods and results 
The methods and results of the clinical trials showing that pamapimod had little or no extra benefit to 
methotrexate in the treatment of rheumatoid arthritis [6] are combined in this section. The trial enrolled 
subjects with rheumatoid arthritis who had initiated methotrexate ≥ 24 weeks before the study and 
were on a stable dose (10-25 mg/week) for ≥ 8 weeks.  The subjects also had to have active disease 
measured as ≥ 6 swollen joints and ≥ 8 tender joints, and C-reactive protein (CRP) levels of ≥ 0.6 
mg/dl or erythrocyte sedimentation rate (ESR) or ≥ 28 mm/h or morning stiffness of ≥ 45 minutes 
duration. 
The 328 subjects enrolled were from 85 international centres, and the median methotrexate dose was 
15 mg, and 55% were using corticosteroids. Patients were retained on methotrexate, and randomised 
to pamapimod at 25 mg bid, 50 mg once daily, 75 mg bid, 150 mg once daily or 300 mg once daily or 
to placebo for 12 weeks.   
The primary efficacy end point was the proportion of subjects with a 20% improvement in the ACR 
criteria (e.g. in tender or swollen joints) after 12 weeks.  The ACR20 response was obtain in 34% of 
subjects in the placebo group and this was mostly increased, but not significantly so, to 40%, 42%, 
40%, 31% and 43% by pamapimod at 25 mg bid, 50 mg, 75 mg bid, 150 mg or 300 mg, respectively. 
Secondary efficacy endpoints included the ACR50 and ACR90, and these were not altered by 
pamapimod.  There are 8 individual components to the ACR criteria, and none of these were altered 
by pamapimod.  Pamapimod also had no effect on the change from baseline in Disease Activity Score 
in 28 joints, categorical analyses of DAS28/European League Against Rheumatics response, 
Changes in the Short Form 36 and Functional Assessment of Chronic Illness Therapy-fatigue or on 
the severity and duration of morning stiffness.  Pamapimod did reduce the levels of CRP at week 1, 
but this effect was not maintained beyond week 4. 
Infections led to withdrawal from treatment in 7 subjects taking pamapimod, compared to the placebo 
group.  For the 88% of subjects who completed the study, in the placebo group, 14 of 53 subjects 
(26%) had infections/infestations, and similar numbers taking pamapimod at 25 mg bid and 50 mg 
had infections/infestations, but higher percentages (35, 43, and 31%) had infections with pamapimod 
at 75 mg bid, 150 or 300 mg, respectively.   
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The higher doses of pamapimod also caused an excess of gastrointestinal disorders and nervous 
system disorders (particularly dizziness), compared to placebo.  Marked elevations in alanine 
aminotransferase and aspartate aminotransferase occurred in similar percentages of placebo and 
pamapimod subjects.  Marked elevation of creatine phosphokinase was more common with the higher 
doses of pamapimod (5.6%) than the lower doses, <150 mg (1.8%) and placebo (0%). 
4.2 Discussion 
This study showed that pamapimod had no efficacy in subjects with rheumatoid arthritis, who had an 
inadequate response to methotrexate [6].  However, there were adverse effects with pamapimod, 
which were similar to those observed with other, chemical distinct p38 MAP kinase inhibitors, and this 
suggests that the adverse effects are related to inhibiting the p38 MAP kinase [6].    
5. Expert opinion 
5.1 Proof-of-concept study 
In addition to showing that there were no significant interaction between pamapimod and 
methotrexate, the study of Zhang et al [5] claimed to be a proof-of-concept study that suggested that 
pamapimod had efficacy in the treatment of rheumatoid arthritis.  There were several problems with 
this efficacy study, and probably the main one is that the study is not big enough to test for small 
changes in disease markers.  The disease activity markers measured were CRP, ESR, SJC and TJC, 
and there was a lot of variation in each of these.  The CRP levels were not matched at baseline, as 
the level was higher in the group that was subsequently treated with pamapimod (0.71 mg/dL) than 
those who received placebo (0.48 mg/dL).  The CRP levels are the same at day 14 (0.47), but this is 
considered to be a decrease on the basis of the higher baseline value in the pamapimod group.  The 
changes in values for ESR, SJC and TJC with placebo and pamapimod are all within the SEM, and 
are not indicated to be significantly different.  The authors claim that ‘Joint counts and acute phase 
reactants were diminished in the pamapimod-treated patients compared to the placebo-treated 
patients, suggesting that pamapimod might be efficacious in adequately powered clinical trials’.  This 
is very tenuous.  
 
In the discussion of the Zhang paper it states that, in subsequent trials, ‘Pamapimod showed weak 
efficacy compared to placebo (which presumably refers to the study in the presence of methotrexate 
by Alten et al [6]) and less efficacious than methotrexate in an active comparable trial’ (which refers to 
the study comparing pamapimod to methotrexate by Cohen et al [4]).  Our reading and interpretation 
of these trials is different, as we consider that the study by Alten et al, showed no efficacy of 
pamapimod in subjects with an inadequate response to methotrexate (Section 4).  Although 
pamapimod did show efficacy compared to placebo in the study of Alten et al [6], the most important 
finding of this trial was that pamapimod was inferior to methotrexate in the treatment of rheumatoid 
arthritis. 
 
5.2 Pamapimod and important mediators of pain and inflammation 
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As discussed in the introduction, theoretically p38α inhibitors should reduce the levels of TNFα, some 
of the interleukins, COX2, RANKL, integrins, MMPs and leukotrienes, and this would be the basis of 
their anti-inflammatory actions.  To our knowledge, pamapimod has only been shown to inhibit LPS-
induced production of TNFα and IL-6, and the spontaneous production of TNFα in synovial explants 
from subjects with rheumatoid arthritis [3].  Thus, in the absence of evidence, it is possible that 
pamapimod is having no or little effect on many mediators of rheumatoid arthritis, and this may 
explain its lack of action.  The effects of pamapimod on the important mediators of pain and 
inflammation in rheumatoid arthritis need to be determined. 
5.3 p38α inhibitors and rheumatoid arthritis – are we using the right animal models? 
There does not seem to be a link between the effectiveness of the p38α inhibitors in certain animal 
models of arthritis and effectiveness in human rheumatoid arthritis.  Thus, in addition to pamapimod, 
the selective p38α inhibitors VX-702 and R-130823, have been shown to be effective in animal 
models of rheumatoid arthritis.  VX-702 was effective in adjuvant-induced and collagen-induced 
arthritis, but like pamapimod, is ineffective in human rheumatoid arthritis [7].  R-130823 was also 
effective in the adjuvant-induced and collagen-induced arthritis, but there is no evidence that it is 
presently being developed for clinical use in rheumatoid arthritis [8].  Methotrexate is not effective in 
the collagen-induced model of arthritis [8] but does have delayed efficacy in carrageenan-induced 
inflammation [9].  This suggests that inhibition of carrageenan-induced inflammation may be a better 
animal model for rheumatoid arthritis than either the adjuvant- or collagen-induced inflammation. 
A new p38α inhibitor, AW-814141, has recently been shown to be effective in the carrageenan-
induced rat paw oedema model, and the collagen-induced arthritis model [10].  It will be of interest to 
know whether AW-814141 is beneficial in human rheumatoid arthritis.   
5.4 Other indications for inhibitors of p38 MAP kinase/TNFα 
Rheumatoid arthritis is not the only disease that p38 MAP kinases and TNFα have been suggested to 
have a pivotal role in.  They are also involved in Crohn’s disease, psoriatic arthritis, and ankolysing 
spondylitis.  Doramapimod (BIRB796) is a p38 MAP kinase inhibitor that reduces the levels of TNFα, 
but clinical trial has shown that it is not effective in active Crohn’s disease [11].  There are no reports 
of clinical trials of p28α inhibitors in psoriatic arthritis or ankolysing spondylitis, to date, and this should 
be checked. 
5.5 Does pamapimod have potential for the treatment of rheumatoid arthritis? 
Despite suggestions by the authors in a proof-of-concept study that the p38α inhibitor pamapimod 
may be efficacious in rheumatoid arthritis [5], this is not supported by larger longer studies of 
pamapimod in combination with methotrexate [6].  Although pamapimod may be superior to placebo 
in rheumatoid arthritis, it is inferior to methotrexate [4].  Thus, it seems to us, that pamapimod does 
not have potential for the treatment of rheumatoid arthritis.  This does not rule out other potential 
clinical uses for pamapimod.  Also, these clinical trials do raise important questions about the role of 
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p38α in pain and inflammation, and (as pamapimod was shown to be effective in preclinical testing) 
the appropriateness of the presently used models of rheumatoid arthritis. 
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